Evidence map›Paper›PMID 31782884›Full record

ArticleMolecular oncology2020

ZNF281/Zfp281 is a target of miR-1 and counteracts muscle differentiation.

Sara Nicolai, Marco Pieraccioli, Artem Smirnov, Consuelo Pitolli, Lucia Anemona, Alessandro Mauriello, Eleonora Candi, Margherita Annicchiarico-Petruzzelli, Yufang Shi, Ying Wang and 2 more

Abstract read
In one paragraph

Article in Molecular oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. ZNF281 Promotes Colon Fibroblast Activation in TGFβ1-Induced Gut Fibrosis.International journal of molecular sciences · 2022
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sara NicolaiMedical Research Council, Toxicology Unit, Department of Pathology, University of Cambridge, UK.ORCID 0000-0001-8776-1440
Marco PieraccioliDepartment of Experimental Medicine, University of Rome Tor Vergata, Italy.ORCID 0000-0003-3995-535X
Artem SmirnovDepartment of Experimental Medicine, University of Rome Tor Vergata, Italy.ORCID 0000-0002-1575-8725
Consuelo PitolliMedical Research Council, Toxicology Unit, Department of Pathology, University of Cambridge, UK.
Lucia AnemonaDepartment of Experimental Medicine, University of Rome Tor Vergata, Italy.ORCID 0000-0002-3711-2714
Alessandro MaurielloDepartment of Experimental Medicine, University of Rome Tor Vergata, Italy.ORCID 0000-0002-7351-5676
Eleonora CandiDepartment of Experimental Medicine, University of Rome Tor Vergata, Italy.ORCID 0000-0001-8332-4825
Margherita Annicchiarico-PetruzzelliIstituto Dermopatico dell'Immacolata-IRCCS, Rome, Italy.ORCID 0000-0002-4717-4740
Yufang ShiCAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China.
Ying WangCAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China.
Gerry MelinoMedical Research Council, Toxicology Unit, Department of Pathology, University of Cambridge, UK.ORCID 0000-0001-9428-5972
Giuseppe RaschellàLaboratory of Health and Environment, ENEA, Rome, Italy.ORCID 0000-0002-6070-577X

Funding

Medical Research Council MC_U132670600Medical Research Council MC_UU_00025/2
6 · The paper itself

Abstract

Defects in achieving a fully differentiated state and aberrant expression of genes and microRNAs (miRs) involved in differentiation are common to virtually all tumor types. Here, we demonstrate that the zinc finger transcription factor ZNF281/Zfp281 is down-regulated during epithelial, muscle, and granulocytic differentiation in vitro. The expression of this gene is absent in terminally differentiated human tissues, in contrast to the elevated expression in proliferating/differentiating ones. Analysis of the 3'UTR of ZNF281/Zfp281 revealed the presence of numerous previously undescribed miR binding sites that were proved to be functional for miR-mediated post-transcriptional regulation. Many of these miRs are involved in differentiation pathways of distinct cell lineages. Of interest, ZNF281/Zfp281 is able to inhibit muscle differentiation promoted by miR-1, of which ZNF281/Zfp281 is a direct target. These data suggest that down-regulation of ZNF281/Zfp281 during differentiation in various cell types may occur through specific miRs whose expression is tissue-restricted. In addition, we found that in rhabdomyosarcoma and leiomyosarcoma tumors, the expression of ZNF281/Zfp281 is significantly higher compared with normal counterparts. We extended our analysis to other human soft tissue sarcomas, in which the expression of ZNF281 is associated with a worse prognosis. In summary, we highlight here a new role of ZNF281/Zfp281 in counteracting muscle differentiation; its down-regulation is at least in part mediated by miR-1. The elevated expression of ZNF281/Zfp281 in soft tissue sarcomas warrants further analysis for its possible exploitation as a prognostic marker in this class of tumors.

Indexed as

AnimalsCell Line, TumorGene Expression ProfilingHumansKaplan-Meier EstimateMiceMicroRNAsMuscle DevelopmentMyoblastsNIH 3T3 CellsPrognosisProtein Processing, Post-TranslationalRepressor ProteinsSarcomaTranscription FactorsMicroRNAsMIRN1 microRNA, humanRepressor ProteinsTranscription FactorsZfp281 protein, mouseZNF281 protein, humanmiRsmuscle differentiationsoft tissue sarcomasZfp281ZNF281

Identifiers

PMID31782884
PMCPMC6998661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.